Finance

Lists
Why is GNLX up 7.69%?
Dive Deeper
GNLX:NASDAQ
Genelux Corp
$1.96
+7.69%
(+0.14) 1D
$1.85
-5.61% (-0.11)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GNLX...
Open
$1.83
High
$2.02
Low
$1.81
Mkt. cap
88.68M
Avg. vol.
376.27K
Volume
323.75K
52-wk high
$6.26
52-wk low
$1.81
EPS
-$0.87
Beta
0.68
Shares outstanding
45.24M
No. of employees
26
Open
$1.83
High
$2.02
Low
$1.81
Mkt. cap
88.68M
Avg. vol.
376.27K
Volume
323.75K
52-wk high
$6.26
52-wk low
$1.81
EPS
-$0.87
Beta
0.68
Shares outstanding
45.24M
No. of employees
26
News stories
From web sources and news partners
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorHealth Care
IndustryBiotechnology
Websitegenelux.com
Analyst ratings
Based on 3 analysts giving stock ratings to GNLX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for GNLX in the last 3 months.
Highest
Current $1.96
$31.00 (+1,481.63%)
Average
$20.33 (+937.24%)
Lowest
$12.00 (+512.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Dev Prasad
Lucid Capital
Buy
Initiated
$18.00
+818.4%
09/16/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$12.00
+512.2%
08/14/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$31.00
+1,481.6%
08/14/2026
Chad Messer
Lake Street
Buy
Maintained
$16.00
+716.3%
06/30/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$20.00
+920.4%
03/20/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
8.00K
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.74M
5.55M
5.73M
6.51M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.45M
3.87M
3.44M
3.14M
Operating expense
8.19M
9.42M
9.17M
9.64M
Total operating expenses
8.19M
9.42M
9.17M
9.64M
Operating income
-8.19M
-9.41M
-9.17M
-9.64M
Other non operating income
69.00K
37.00K
70.00K
47.00K
EBT including unusual items
-7.95M
-9.25M
-8.93M
-9.47M
EBT excluding unusual items
-7.95M
-9.25M
-8.93M
-9.47M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7.95M
-9.25M
-8.93M
-9.47M
Net profit margin
-
-115,587.50%
-
-
Earnings per share
-0.21
-0.24
-0.20
-0.21
Interest and investment income
175.00K
128.00K
173.00K
127.00K
Interest expense
-
-
-
-
Net interest expenses
175.00K
128.00K
173.00K
127.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.13M
-9.35M
-9.16M
-9.63M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps